Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Newmont Corporation (NEM) vs Novo Nordisk A/S (NVO) Price & Performance

Newmont CorporationTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Newmont Corporation vs Novo Nordisk A/S — how do they compare? Newmont Corporation trades at $118.07 (market cap $123.50B), while Novo Nordisk A/S trades at $46.28 (market cap $207.85B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

NEMNVO
Market Cap
$123.50B$207.85B
Sector
Basic MaterialsHealth
52-Week High
$131.95$63.98
52-Week Low
$67.38$35.29
Enterprise Value
$120.09B$222.55B
Dividend Yield
0.89%3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Newmont Corporation

Newmont (NEM) trades at $118.52, up 1.07% on the day, with strong earnings beats in recent quarters and a bullish analyst consensus. Technical indicators show mixed signals with RSI near overbought levels but moving averages supporting an uptrend. Recent news highlights resolution of a Nevada dispute with Barrick and solid Q2 2026 results, reinforcing operational stability.

Outlook remains positive with a $133 consensus price target, driven by robust cash flow and gold price strength. Risks include potential cost pressures and reliance on commodity cycles, but institutional buying and high buy ratings suggest confidence in near-term growth.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Newmont Corporation

Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.

Read more on NEM

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO